fbpx
Lesson 6, Topic 7
In Progress

Key Guidelines and Evidence

Lesson Progress
0% Complete
  • AAP Guidelines on Palivizumab Prophylaxis (Pediatrics 2014)
    • Palivizumab prophylaxis recommendations for high-risk infants
    • Maximum 5 monthly doses; no routine use beyond age 24 months
    • Moderate recommendation, high quality evidence
  • AAP Guidelines on Ribavirin (Pediatrics 2006)
    • Ribavirin lacks efficacy for RSV lower respiratory tract disease
    • Routine use not recommended
    • Strong recommendation, moderate quality evidence
  • Cochrane Review (2021)
    • Bronchodilators have limited efficacy for RSV bronchiolitis
    • Routine use not recommended
    • High quality evidence